SAUSALITO, Calif., Jan. 24, 2012 /PRNewswire/ -- Sanovas, a leading developer of innovative micro-surgical devices for diagnosing and treating cancer and chronic diseases, announced today that it has expanded its corporate headquarters and opened a manufacturing site in Sausalito, Calif. The facility will initially manufacture critical components of Sanovas' technology ahead of filing for U.S. Food and Drug Administration approval, and would ultimately serve to produce Sanovas' commercial products.
"Sanovas' headquarters is a natural choice for our manufacturing site, as it allows us to maintain the highest level of quality control over the most proprietary components of our technology platform," CEO Larry Gerrans said. "These facilities will provide us with the ability to attract the very best talent from within the life sciences community right here in the Bay Area."
Sanovas' micro-surgical technology platform is designed to give surgeons the ability to access and understand previously inaccessible areas of the body, enabling them to diagnose, treat and deliver drug and immune therapies to small diameter anatomy in entirely new ways. Developed by the pioneers in the field of minimally invasive devices, this intelligent micro-surgical technology platform utilizes the world's smallest surgical camera to visualize and treat difficult-to-reach areas of the body. The camera is connected to the end of a steerable catheter that is further used to deliver additional tools for collecting tissue samples, analyzing and removing tumors and delivering drug and immune therapies to targeted locations within the deepest reaches of the body.
Sanovas plans to file a 510(K) submission with the FDA within the first half of 2012 for approval of its technology, and if approved, would begin full-scale manufacturing by the end of the year. Initially, Sanovas intends to market its micro-surgical tools for the treatment of lung cancer and pulmonary disease. Lung cancer is the leading cause of cancer death among men and women worldwide, and nearly 400,000 people in the United States die from lung disease each year, according to the American Lung Association.
"With nearly one in seven Americans currently suffering from a chronic pulmonary disease and another 96 million at risk, there is an urgent humanitarian need for these next-generation solutions," Gerrans said.
Sanovas, Inc., based in Sausalito, Calif., is a leading developer of innovative micro-surgical devices for diagnosing and treating cancer and chronic diseases. Sanovas' micro-surgical technology platform is designed to give surgeons the ability to access and visualize previously inaccessible areas of the body; enabling them to diagnose, treat and deliver drug and immune therapies to small diameter anatomy in entirely new ways. The company plans to commercialize its technology platform, which will initially address the unmet needs in lung cancer and pulmonary disease, in 2012. Privately held Sanovas was founded by the pioneers in minimally invasive surgery. The company has more than 25 multi-national patents pending.
Marla Kertzman, 415-694-6701
Copyright©2010 PR Newswire.
All rights reserved